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ABSTRACT 
Oral fingolimod has been recently accepted as a treatment for relapsing Multiple Sclerosis 
(MS) by the Indonesian Food and Drug Administration. The number of MS patients is increasing 
in Indonesia. There is a critical need of systematically reviewing the new medication for both 
efficacy and safety. This review aimed to appraise the clinical evidences of oral fingolimod for the 
effective treatment of relapsing MS. We searched in Pubmed database. We limited our search to 
only articles that were in full text, published within the last 10 years, and in English. We used the 
Jadad scale to measure the quality of the evidences. We only found 3 trials, all conducted with 
randomized and double blind design. The three trials were: the FREEDOMS I, FREEDOMS II, 
and TRANSFORMS studies. The FREEDOMS studies compared with placebo, and the 
TRANSFORMS study compared with injectable interferon. All of the studies have good quality in 
methodology (Jadad scale >3). The results of the three studies showed the benefit of oral 
fingolimod in reducing MS relapse compared with placebo with relative risk reduction range from 
48% to 54%, and also in reducing new lesions in T2 brain MRI with relative risk reduction range 
from 35% to 74%. Our critical appraisal found that oral fingolimod improved clinical outcomes. 
The availability of oral fingolimod in Indonesia makes it one of the options in treatment of MS 
relapse in Indonesia and has been demonstrated to be effective and safe with relatively small risk.  
Keywords: critical appraisal, fingolimod, multiple sclerosis, relapsed MS, Indonesia 
 
ABSTRAK 
Fingolimod oral baru-baru ini memiliki Nomor Ijin Edar (NIE) dari BPOM untuk multipel 
sklerosis. Jumlah kasus multipel sklerosis meningkat di Indonesia. Ada kebutuhan untuk melakukan kajian 
sistematis terhadap efektivitas dan keamanan obat-obat untuk multipel sclerosis. Tujuan dari penelitian ini 
adalah untuk menilai berbagai penelitian klinis pada fingolimod untuk terapi multipel sklerosis yang 
relaps. Peneliti melakukan pelacakan pustaka di Pubmed. Pencarian hanya dibatasi untuk artikel yang 
dapat diperoleh secara bebas, terbit 10 tahun terakhir, dan dipublikasi dalam bahasa inggris. Peneliti 
menggunakan skor Jadad untuk menilai kualitas penelitian. Kami hanya menjumpai 3 uji klinik dengan 
disain randomisasi dan double blind. Ketiga uji klinik tersebut adalah: uji klinik FREEDOMS I, uji klinik 
FREEDOMS II, dan uji klinik TRANSFORMS. Uji klinik FREEDOMS membandingkan fingolimod dengan 
placebo, dan uji klinik TRANSFORMS membandingkan fingolimod dan interferon injeksi. Semua uji klinik 
tersebut memiliki kualitas yang baik (skor Jadad >3). Ketiga uji klinik menunjukkan manfaat fingolimod 
dalam mengurangi relaps disbanding dengan placebo antara 48%-54%, dan juga mengurangi lesi baru di 
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MRI kepala T2 dengan penurunan risiko relatif berkisar antara 35%-74%. Telaah kritis menunjukkan 
adanya perbaikan luaran dengan fingolimod. Ketersediaan fingolimod di Indonesia menjadikannya 
sebagai salah satu pilihan dalam terapi efektif dan aman untuk multipel sclerosis di Indonesia. 
Kata kunci: telaah kritis, fingolimod, multiple sclerosis, relapse MS, Indonesia 
 
 
 
INTRODUCTION 
Multiple sclerosis (MS) is an immune 
mediated condition that leads to central nervous 
system (CNS) deterioration (Fitzner and Simons, 
2010). In daily clinical practice, over 80% of 
patients with MS are identified as Remission-
Relapse, which is the most common subtype of the 
disease (Steinman, 2014). The cause of MS is not 
known (Loma and Heyman, 2011). Genetics 
(including race and gender), Epstein-Barr virus 
infection, and environmental factors (vitamin D 
deficiency, smoking, geographical location, low 
exposure to sunlight, birth month) are linked to the 
disease (Bagheri et al., 2015; O’Gorman et al., 
2012; Oreja-Guevara et al., 2014). Multiple 
sclerosis is thought to be an autoimmune disease 
mediated by T-cells that leads to the breakdown of 
the blood brain barrier, allowing inflammatory 
mediators to enter and attack the CNS, resulting in 
demyelination and axonal loss (Kasper and Reder, 
2014; Wu and Alvarez, 2011). Diagnosis of MS is 
based on clinical symptoms in combination with 
evidence of lesions from magnetic resonance 
imaging (MRI) (Polman et al., 2011). Symptoms 
vary depending on the location and severity of the 
CNS lesions (Marcus and Waubant, 2012).  
Multiple sclerosis is a chronic disease that 
can progress intermittently or continuously and is 
divided into four disease courses: (1) relapsing-
remitting multiple sclerosis (RRMS), (2) primary-
progressive multiple sclerosis (PPMS), (3) 
secondary-progressive multiple sclerosis (SPMS), 
and (4) progressive-relapsing multiple sclerosis 
(PRMS) (Leary et al., 2005; Lublin et al., 2014). 
Relapsing-remitting multiple sclerosis is the most 
common form of MS (Huisman et al., 2017). Most 
medications used in the treatment of MS are 
indicated in the treatment of RRMS (Kieseier and 
Jeffery, 2010). 
Relapses are common and represent a major 
feature of MS (Ross, 2012). A relapse is 
characterized by episodes of acute worsening of 
function followed by partial or complete recovery 
(McKay et al., 2015). The outcome measure of 
limitations to parenteral disease-modifying 
therapies (DMTs) such as interferon (IFN) -β-1a, 
IFN-β-1b, and glatiramer acetate for the treatment 
of RRMS (Weinstock-Guttman, 2013) have been 
addressed by the approval of oral DMT-
fingolimod in Indonesia. Fingolimod is an 
immunotherapeutic drug targeting the sphingosine-
1-phosphate receptor, and is a widely used 
medication for RRMS (Ayzenberg et al., 2016) 
which is metabolized by sphingosine kinase to the 
active metabolite fingolimod phosphate which in 
turn blocks the migration of lymphocytes from 
lymph nodes, thereby reducing the number of 
lymphocytes in peripheral blood (Goldenberg, 
2012). 
The number of multiple sclerosis patients is 
increasing in Indonesia. There is a critical need of 
systematically reviewing the new medication for 
multiple sclerosis both for efficacy and safety. The 
aim of this review is to appraise the clinical 
evidences of oral fingolimod for the effective 
treatment of relapsing MS.  
 
METHODS 
A literature search was conducted to identify 
articles addressing each key question, searching 
the MEDLINE database, the Cochrane Library, 
and reference lists of review articles. We searched 
in Pubmed database using keywords: fingolimod, 
multiple sclerosis patients, relapsing multiple 
sclerosis, and clinical trial. We limited our 
searches only for articles that were full text, 
published within the last 10 years, and in English. 
We used the Jadad scale to measure the quality of 
the evidences (Berger and Alperson, 2009). For 
the clinical efficacy section, only clinical trials 
published in English and indexed on MEDLINE, 
evaluating efficacy of fingolimod with reduction 
of symptoms or improvement in disease state as an 
endpoint were included. Trials evaluating 
fingolimod as monotherapy or combination 
therapy where adjunctive medications remained 
constant throughout the trial were also included. 
Trials comparing monotherapy with combination 
regimens were excluded.  
We excluded clinical trials which evaluated 
endpoints other than reduction of symptoms, such 
as lymphocyte count, or immune response. 
Individual trials comparing fingolimod in dose-
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finding studies or in healthy subjects were also 
excluded. We measured the quality of the 
evidences using the Jadad score for evaluating the 
clinical trial. We calculated the absolute risk 
reduction (ARR), the relative risk reduction 
(RRR), and number needed to treat (NNT) for the 
dichotomous important clinical outcome which 
was compared with placebo. This review appraised 
the validity and significance of the previous 
studies of fingolimod as an effective MS medicine. 
We also appraised its applicability as a safe 
treatment for relapsing MS in the Indonesia 
setting.  
 
RESULTS AND DISCUSSION 
We found 18 trials that measured the 
effectiveness of oral fingolimod in relapsing 
multiple sclerosis. We only found 3 trials which 
were randomized controlled trials (RCTs) with 
double blind design. The three trials are: 
FREEDOMS I, FREEDOMS II, and 
TRANSFORMS studies. The FREEDOMS studies 
compared with placebo and the TRANSFORMS 
study compared with injectable interferon. All of 
the studies have good quality in methodology 
(Jadad scale >3). 
The FREEDOMS studies were placebo-
controlled, double-blind RCTs that compared two 
doses of fingolimod, 0.5 mg and 1.25 mg once 
daily, to placebo over a period of 2 years. There 
were 1272 patients enrolled, with 59% of whom 
had never previously been on any form of DMT. 
The primary endpoint was the annualized relapse 
rate over the full 2-year study period with other 
clinical and radiological outcomes examined as 
secondary endpoints. The annualized relapse rate 
was 0.40 in the placebo arm, 0.18 in the low dose 
and 0.16 in the high dose fingolimod arms, 
corresponding to Relative Risk Reductions (RRR) 
of 54% and 60%, respectively (p <0.05).   
 
 
Table I. Descriptions of the Study 
Study Method Comparator Subjects Result 
FREEDOMS I 
Randomized, 
double blind 
Placebo 
1272 patients, 
1033 completed 
the study 
Significant reduction of relapse rate in 
the Fingolimod group (0.16 vs 0.40, p 
<0.001) 
FREEDOMS II 
Randomized, 
double blind 
Placebo 
1083 subjects, 
divided into 3 
groups 
Significant reduction in relapse rate 
compared with placebo (0.21 vs 0.40, p 
<0.05) 
TRANSFORMS 
Randomized, 
double blind 
Interferon 
beta 
1292 subjects 
Significant lower relapse rate either in 
0.5 mg or 1.25 mg Fingolimod 
compared with Interferon (0.16 vs 0.20 
vs 0.33, p <0.05) 
 
Table II. The Quality Assessment of the Trials 
Trials 
Is it 
randomized? 
Is it double 
blind? 
Is 
randomization 
appropriate? 
Is the blinding 
appropriate? 
Is there any 
description of 
withdrawals 
and drop outs? 
FREEDOMS I Yes Yes Yes Yes Yes 
FREEDOMS II Yes Yes Yes Yes Yes 
TRANSFORMS Yes Yes Yes Cannot tell Yes 
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Table III. The Summary of Effectiveness of the Study 
Trials Relapse Rate New Lesion in T2 
Confirmed 
Disability 
Progression 
Brain Volume 
Loss 
FREEDOMS I -54% -74% -34% -35% 
FREEDOMS II -48% -74% -28% -33% 
TRANSFORMS -52% -35% No data -31% 
 
Table IV. The Calculation of ARR, RRR, and NNT for Annualized Relapse Rate 
Trials  CER EER 
RRR 
(CER-EER) : CER 
ARR 
(CER-EER) 
NNT/ 
ARR 
FREEDOMS I 0.40 0.18 55% 22% 4.5 
FREEDOMS II 0.40 0.21 47.5% 19% 5.2 
TRANSFORM 0.33 0.16 51% 17% 5.88 
EER: Experimental Event Rate, CER: Control Event Rate, ARR: Absolute Risk Reduction, RRR: Relative Risk 
Reductions, NNT: Number Needed to Treat 
 
In contrast to FREEDOMS, 
TRANSFORMS was a 1-year long, double-blind, 
double-dummy RCT using an established DMT, 
with weekly intramuscular IFN-1a as an active-
comparator. A total of 1292 patients (45% 
treatment-naïve) were randomized in a 1:1:1 
treatment allocation. The primary endpoint was the 
annualized relapse rate, while similar secondary 
MRI and clinical endpoints were also assessed. 
The annualized relapse rates were 0.16 in the 0.5 
mg arm and 0.20 in the 1.25 mg arm in contrast to 
0.33 in the IFN-1a-treated subjects, corresponding 
to RRRs of 52% and 38%, respectively (p <0.05). 
This review showed that high quality 
evidences support the use of oral fingolimod as a 
safe and effective DMT in MS. Treatment of MS 
varies depending on the clinical subset of MS 
present and individual patient characteristics. In 
general, treatment may include treatment of acute 
relapses, DMT in combination with symptomatic 
treatment, and complications associated with MS 
(Pandit and Murthy, 2011). Treatments of 
moderate-severe acute MS relapses include 
systemic corticosteroids or adrenocorticotropic 
hormone (ACTH) therapy (Berkovich, 2013). 
Symptomatic treatments include glucocorticoid 
therapy, benzodiazepines, muscle relaxers, 
anticonvulsants, antidepressants, and medications 
used to treat bladder and bowel dysfunction 
(Antezana, 2014). Currently, no curative 
medication therapies are available in the treatment 
of MS (Mendes and Sá, 2011). DMTs provide 
symptomatic relief and reduced MS progression. 
Many injectable DMTs and oral agents are 
available for use in MS (Longbrake et al., 2016). 
DMTs include IFN-β-1a, IFN-β-1b, glatiramer 
acetate, teriflunomide, dimethyl fumarate (as the 
first line medications), mitoxantrone, 
alemtuzumab, natalizumab, and fingolimod (as the 
second line medications) (Torkildsen et al., 2015).  
The IFN-β agents have anti-inflammatory 
properties as well as their effects on the 
endothelial cells of the blood brain barrier 
(Minagar, 2013). Glatiramer acetate is associated 
with a broader immunomodulatory effect on both 
the innate and adaptive immune system (Lalive et 
al., 2011). Teriflunomide acts primarily as an 
inhibitor of dihydroorotate-dehydrogenase, thereby 
diminishing the inflammatory response to auto-
antigen (Oh and O’Connor, 2014). Dimethyl 
fumarate has immunomodulatory properties 
exerted through abilities to divert cytokine 
production toward a Th2 profile (Bomprezzi, 
2015). Mitoxantrone is an immunosuppressive 
drug and considered as an effective therapeutic 
option in RRMS, but the potential life-threatening 
adverse events and the overall benefit-risk ratio 
must be carefully evaluated at the individual 
patient level (Esposito et al., 2010). Both 
alemtuzumab, an anti-CD52 antibody, and 
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natalizumab seem highly effective and viable 
immunotherapies for MS (Kalincik et al., 2017). 
The trials showed that fingolimod 
significantly improved annualized relapse rates 
and MRI endpoints when compared to IFN and 
placebo. Most of its benefits are neuroprotective 
and reparative (Williams et al., 2014). Our critical 
appraisal and evaluation of fingolimod, the oral 
sphingosine-1- phosphate (S1P) inhibitor, suggests 
fingolimod is safe and effective in reducing acute 
MS attacks and may be a more convenient 
treatment option for patients. 
Fingolimod has proven its effectiveness in 
reducing relapse rate, disability progression, MRI 
activity, and brain volume loss (Fonseca, 2015). In 
MS, fingolimod appears to prevent normal 
lymphocyte egress from lymphoid tissues, thus 
reducing the infiltration of autoaggresive 
lymphocytes into the CNS, where they would 
cause inflammation and tissue damage (Chun and 
Hartung, 2010). The clinical data showed that 
lymphocyte count decreases within 6 hours of the 
first dose of fingolimod and will return to normal 
1-2 months after discontinuing the drug. 
Fingolimod therapy also results in decreased 
neutrophil count but does not reduce monocyte 
count (Archer and Oderda, 2013). 
The long half-life of fingolimod, together 
with its slow absorptions, means that fingolimod 
has a flat concentration profile over time with 
once-daily dosing (David et al., 2012). After 
administration, fingolimod is largely distributed 
into red blood cells, has a large volume of 
distribution (1,200 L), is highly plasma protein 
bound and is primarily metabolized by hepatic 
CYP4F2. Fingolimod is renally excreted and no 
dosage adjustments are required for patients with 
renal or hepatic dysfunction (Archer and Oderda, 
2013).  
Treatment with fingolimod was well 
tolerated and no patients had any severe adverse 
events (Totaro et al, 2015). This review revealed 
there were some side effects from administering 
fingolimod, such as bradycardia, first or second 
heart block, macular edema, increased serum 
alanine aminotransferase (ALT), lymphopenia, and 
infection. Most of those side effects were 
infrequent and resolved with discontinuation of 
fingolimod (Nicholas et al., 2012).  
Multiple sclerosis is a chronic disabling 
condition. The prevention of relapse is the main 
objective of multiple sclerosis management 
(Berkovich, 2013). This review found that the 
Number Needed to Treat (NNT) for prevention of 
one relapse is 5. It means that we have to treat 5 
patients with multiple sclerosis to prevent one 
relapse during the treatment period. The NNT 
between 2-5 indicates that the medication is 
effective (Berger and Alperson, 2009). Fingolimod 
oral administration is simpler than subcutaneous 
interferon injection. It makes fingolimod more 
applicable in clinical setting.  
  
CONCLUSION 
Fingolimod was the first introduced oral 
disease-modifying agent approved for the 
treatment of relapsing MS. Our critical appraisal 
found that oral fingolimod improved clinical 
outcomes. Fingolimod also has relatively good 
tolerability. The availability of oral fingolimod in 
Indonesia makes it one of the safe and effective 
options in the treatment of multiple sclerosis in 
Indonesia. Oral administration of fingolimod 
makes it more applicable in clinical setting 
compared with subcutaneous interferon injection. 
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